Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer

NCT04977596 | Completed DMC

• 1 other identifier: yurisheng
• Study Type: observational
• Target: 78
• Locations: 1 country
• Sites: 1

Brief Summary

1. 1.Imaging findings (including CT and MRI images) of both well-differentiated G3 PNET and poorly differentiated PNET were studied;
2. 2.The CT imaging findings of G3 stage PNET and pancreatic cancer were compared to establish a Logistic regression diagnostic model, and the survival analysis of the two was compared.
3. 3.Cox regression was used to study the risk factors for survival prognosis of well-differentiated and poorly differentiated PNET based on CT image features

Conditions

Neuroendocrine Tumor of Pancreas; Carcinoma, Pancreatic; CT

Outcome Measures

Primary Outcomes (17)

• Tumor size

  Maximum surface size of the lesion (cm)

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• Tumor location

  Locations of the pancreas: head, neck, body and tail

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• Number of lesions

  Number of lesions

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• Margin

  well-defined or ill-defined

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• tumor texture

  solid；solid and cystic；complex cystic

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• Pancreatic tail contraction

  yes or no

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• Complicated pancreatitis

  yes or no

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• Pancreatic duct/bile duct dilatation

  yes or no

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• Extrapancreatic tissue invasion

  yes or no

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• Hepatic metastasis

  yes or no

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• Lymphatic metastasis

  yes or no

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• CT value of pancreas plain scan

  CT value of pancreas plain scan

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• CT value of lesion plain scan

  CT value of lesion plain scan

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• CT value of pancreas artery phase

  CT value of pancreas artery phase

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• CT value of lesion artery phase

  CT value of lesion artery phase

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• CT value of pancreas portal phase

  CT value of pancreas portal phase

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

• CT value of lesion portal phase

  CT value of lesion portal phase

  preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

Study Arms (2)

Group PNETs

The investigators retrospectively analyzed data for patients who underwent contrast-enhanced MDCT for the evaluation of G3 PNETs at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 12) between January 2011 and May 2019, patients with G3 PNET who underwent MDCT at the First Affiliated Hospital of Zhejiang University School of Medicine (n = 4) and the Military Medical University of Air Force (The Fourth Military Medical University) (n = 4) between January 2013 and October 2018

Other: No intervention

Group PDAC

Patients with PDAC who underwent MDCT at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 58) from February 2014 to August 2015.

Other: No intervention

Interventions

No intervention OTHER

Retrospective study without intervention

Group PDAC; Group PNETs

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The investigators retrospectively analyzed data for patients who underwent contrast-enhanced MDCT for the evaluation of G3 PNETs at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 12) between January 2011 and May 2019, patients with G3 PNET who underwent MDCT at the First Affiliated Hospital of Zhejiang University School of Medicine (n = 4) and the Military Medical University of Air Force (The Fourth Military Medical University) (n = 4) between January 2013 and October 2018, and consecutive patients with PDAC who underwent MDCT at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 58) from February 2014 to August 2015.

You may qualify if:

• Diagnosis by pathology and detailed pathological information
• Enhanced CT examination or biopsy were performed within 2 months before surgery
• There was no preoperative radiotherapy or chemotherapy

You may not qualify if:

• No Ki-67 index
• CT value cannot be measured by ROI because of pancreatic atrophy and other reasons
• No enhanced images or missing images

Sponsors & Collaborators

• Second Affiliated Hospital, School of Medicine, Zhejiang University: lead
• Zhejiang University: collaborator
• The First Affiliated Hospital of the Fourth Military Medical University: collaborator

Study Sites (1)

Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310009, China

Location

MeSH Terms

Conditions

Adenoma, Islet Cell; Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Adenoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Study Officials

• Risheng Yu

  Second Affiliated Hospital of Zhejiang University School of Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 12, 2021
• First Posted: July 27, 2021
• Study Start: January 1, 2012
• Primary Completion: January 1, 2019
• Study Completion: June 25, 2019
• Last Updated: July 27, 2021

Record last verified: 2020-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)